Clinical Trials

Carcinoma, Non-Small-Cell Lung

NCT07416474 2026-04-20

RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)

Phase 3 Recruiting

574 enrolled

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07502300 2026-04-20

A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07)

562 enrolled

Small Cell Lung Carcinoma

NCT03967977 2026-04-17

Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma

420 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT05152147 2026-04-17

HERIZON-GEA-01

920 enrolled

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms, Stomach Neoplasms

NCT06233981 2026-04-17

Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thrombosis

Phase 2 Completed

30 enrolled

Carcinoma, Hepatocellular

NCT06427941 2026-04-17

A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

140 enrolled

Phase NA Not yet recruiting

Simpson-Golabi-Behmel syndrome, Carcinoma, Hepatocellular

NCT07535840 2026-04-17

A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular Carcinoma

25 enrolled

Phase 2 Active not recruiting

Carcinoma, Hepatocellular

NCT05635708 2026-04-15

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

400 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06233942 2026-04-15

Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors

308 enrolled

Advanced Solid Tumor

NCT06596473 2026-04-15

A Study of BG-C477 in Participants With Advanced Solid Tumors

310 enrolled

Advanced Solid Tumors

NCT06745908 2026-04-15

ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer

Phase 3 Recruiting

460 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04164199 2026-04-14

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

404 enrolled

Advanced Malignancies

NCT07528274 2026-04-14

Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure

20 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03957590 2026-04-13

A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma

Phase 3 Completed

370 enrolled 17 charts

Phase 2 Not yet recruiting

Esophageal Squamous Cell Carcinoma

NCT07518706 2026-04-09

Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin

60 enrolled

Carcinoma, Hepatocellular

NCT06422520 2026-04-06

A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors

120 enrolled

Advanced Solid Tumor

NCT07136077 2026-04-06

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

20 enrolled

Phase 2 Active not recruiting

Colorectal Neoplasms, Neoplasm, Residual

NCT07512674 2026-04-06

Modified Short-Course Radiotherapy Combined With Immunochemotherapy and Targeted Therapy as First-Line Treatment for MSS Metastatic Colorectal Cancer

33 enrolled

Patients With Initially Unresectable MSS-type Advanced Colorectal Cancer With Liver and/or Lung and Peritoneal Metastasis

NCT06848465 2026-04-03

LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver Metastasis

9 enrolled

Phase 1/2 Not yet recruiting

Colorectal Neoplasms

NCT03744468 2026-04-02

Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors

Phase 1/2 Completed

147 enrolled 74 charts

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung

NCT07468071 2026-04-02

KontRASt-R

40 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT05516914 2026-04-01

A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors

Phase 1/2 Completed

98 enrolled

Tumor-Agnostic

Neoplasms

NCT07390383 2026-04-01

A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]

Phase 2 Not yet recruiting

110 enrolled

Phase 1/2 Not yet recruiting

Advanced Solid Tumour

NCT07502768 2026-03-31

EpiRev-NKT

107 enrolled

Lymphoid

Recurrence, Lymphoma, Extranodal NK-T-Cell

NCT05984602 2026-03-30

A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer

9 enrolled

Gastrointestinal Neoplasms, Pancreatic Neoplasms

NCT06868732 2026-03-30

Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC

288 enrolled

Advanced Non-small Cell Lung Cancer

NCT05768932 2026-03-27

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

BreastGastrointestinalOther hematologic neoplasm

260 enrolled

Carcinoma, Stomach Neoplasms, Leukemia, Myeloid, Acute, Triple Negative Breast Neoplasms

NCT05982522 2026-03-27

IN10018 Combination Therapy in Previously-treated Solid Tumors

Phase 1/2 Withdrawn

Solid Tumor

NCT04387084 2026-03-23

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

10 enrolled

Dermatologic

Skin Neoplasms

NCT06897579 2026-03-23

Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer

134 enrolled

Phase 1/2 Active not recruiting

Extensive Stage Small Cell Lung Cancer

NCT05661955 2026-03-20

A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.

113 enrolled

DermatologicGenitourinary

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma

NCT07485920 2026-03-20

A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung Cancer

Phase 4 Not yet recruiting

20 enrolled

Small Cell Lung Carcinoma

NCT05981703 2026-03-19

A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

217 enrolled

Advanced Solid Tumor

NCT04379635 2026-03-18

Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)

453 enrolled

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04699188 2026-03-18

KontRASt-01

344 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

NCT06487858 2026-03-18

A Study of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Solid Tumors

75 enrolled

Solid Tumor

NCT06585488 2026-03-18

A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

GastrointestinalOther solid neoplasmThoracic

514 enrolled

Metastatic Solid Tumors

NCT06540066 2026-03-16

A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors

Phase 1 Terminated

35 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT07475026 2026-03-16

A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence

Phase 3 Not yet recruiting

198 enrolled

Phase 2 Not yet recruiting

Carcinoma, Hepatocellular

NCT05935098 2026-03-13

BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors

Phase 1 Terminated

99 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT07469306 2026-03-13

Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer

130 enrolled

Locally Advanced Rectal Cancer

NCT07120282 2026-03-09

Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC

108 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07331155 2026-03-09

A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]

110 enrolled

Phase 2 Active not recruiting

Advanced Solid Tumour

NCT05502250 2026-03-06

HOVON164HL

75 enrolled

Lymphoid

Hodgkin Disease

NCT06647680 2026-03-06

Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）

35 enrolled

Phase 1 Not yet recruiting

Pathologic Complete Response, Rectal Neoplasms

NCT07453875 2026-03-06

TRIUNITE06

9 enrolled

Colorectal Neoplasms

NCT05526924 2026-03-04

Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer